Zurcher Kantonalbank (Zurich Cantonalbank) Affimed N.V. Transaction History

Zurcher Kantonalbank (Zurich Cantonalbank)

$32.8 Billion
Q3 2024

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 21, 2022	SELL	$3.69 - $5.65 $33,364 - $51,087	-9,042 Closed	0 $0
Q4 2021 Feb 01, 2022	SELL	$5.37 - $7.07 $4,892 - $6,440	-911 Reduced 9.15%	9,042 $50,000
Q3 2021 Nov 15, 2021	BUY	$5.54 - $7.51 $1,584 - $2,147	286 Added 2.96%	9,953 $62,000
Q1 2021 May 03, 2021	BUY	$5.12 - $8.48 $49,495 - $81,976	9,667 New	9,667 $76,000

Others Institutions Holding AFMD

# of Institutions

Shares Held

1.09M

Call Options Held

Put Options Held

Tekla Capital Management LLC

586K
Shares

$2.04 Million
0.01% of portfolio
Act Capital Management, LLC Wayne, PA

309K
Shares

$1.07 Million
0.88% of portfolio
Telemetry Investments, L.L.C. New York, NY

200K
Shares

$696,000
0.39% of portfolio

View Full List

About Affimed N.V.

Ticker AFMD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,339,008
Market Cap $520M
Description
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and rest of Europe. Its lead product candidate is AFM13, which has completed Phase II clinical study for peripheral T-cell lymphoma; in Phase IIa clinical trial for CD30-positive lymphoma; and in P...

More about AFMD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.

Account